<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815488</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-06297AA1-01</org_study_id>
    <secondary_id>2015-003075-30</secondary_id>
    <nct_id>NCT02815488</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD</brief_title>
  <acronym>CHF6297 FIH</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF 6297 After Single and Repeated Ascending Doses in Healthy Male Subjects Followed by a Repeated Dose in COPD Patients and a 2-way, Crossover, Double-blind, Placebo-controlled, Repeated Dose Part to Investigate the Anti-inflammatory Effect of CHF 6297 After Lipopolysaccaride (LPS) Challenge in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHF6297 is a potent and selective inhibitor of human MAP kinase p38 being developed as an
      anti-inflammatory agent for the treatment of inflammatory airways diseases. The purpose of
      this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      single and repeat doses of CHF6297 as dry powder formulation in healthy subjects and in COPD
      patients. This study is the first administration in humans.

      The study will comprise four parts:

      Part 1 will consist of two cohorts of healthy male subjects to assess the safety,
      tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF6297.

      Part 2 will consist of four cohorts of healthy male subjects to assess the safety,
      tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6297.

      Part 3 will consist of one cohort of COPD patients to assess the safety, tolerability,
      pharmacokinetics and pharmacodynamics of a repeat dose of CHF6297

      Part 4 will consist of one cohort of healthy subjects to assess the anti-inflammatory effect
      of a repeat dose of CHF6297 after LPS challenge.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Further ongoing animal safety investigations
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Part 1 from Day 1 until Day 4, Part 2 from Day 1 until Day 8, Part 3 from Day 1 until Day 17, Part 4 from Day 1 until Day 8</time_frame>
    <description>Treatment-related Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital signs</measure>
    <time_frame>Part 1 from Day 1 until Day 4, Part 2 from Day 1 until Day 8, Part 3 from Day 1 until Day 17</time_frame>
    <description>Blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Holter ECG parameters</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 7-8, Part 3 Day 1-2 and Day 14-15</time_frame>
    <description>HR, QTcF, PR, QRS + holter recording abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1 and Day 7-8, Part 3 Day 1, Day 10 and Day 14</time_frame>
    <description>Forced exhalation volume in the first second</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Laboratory parameters</measure>
    <time_frame>Part 1 Day 1 and Day 4, Part 2 Day 1 and Day 8, Part 3 Day 1 and Day 15</time_frame>
    <description>Clinical chemistry and haematology + urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs time curve</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
    <description>maximum plasma concentration of CHF6297</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration (tmax)</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
    <description>Absolute plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Part 1 Day 1 until Day 4, Part 2 Day 1 and Day 7, Part 3 Day 1 and Day 14</time_frame>
    <description>plasma volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion (Ae)</measure>
    <time_frame>Part 1 from Day 1 to Day 4, Part 2 Day 1 and Day 7</time_frame>
    <description>Amount of CHF6297 excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fraction excreted (fe)</measure>
    <time_frame>Part 1 from Day 1 to Day 4, Part 2 Day 1 and Day 7</time_frame>
    <description>Percentage of drug excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>Part 1 from Day 1 to Day 4, Part 2 Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 3: markers of inflammation (exploratory)</measure>
    <time_frame>after 14 days of dosing</time_frame>
    <description>Blood and sputum biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 4: markers of inflammation (exploratory)</measure>
    <time_frame>after 7 days of dosing</time_frame>
    <description>Blood and sputum biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>CHF6297 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6297 (Part 1 - SAD)</intervention_name>
    <description>Single doses of CHF6297 at each period (for up to 3 periods per subject)</description>
    <arm_group_label>CHF6297 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 1 - SAD)</intervention_name>
    <description>Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6297 (Part 2 - MAD)</intervention_name>
    <description>Twice daily doses of CHF6297 for 7 days</description>
    <arm_group_label>CHF6297 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 2 - MAD)</intervention_name>
    <description>Twice daily doses of placebo matching CHF6297 for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6297 (Part 3)</intervention_name>
    <description>Twice daily doses of CHF6297 for 14 days</description>
    <arm_group_label>CHF6297 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 3)</intervention_name>
    <description>Twice daily doses of placebo matching CHF6297 for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6297 (Part 4)</intervention_name>
    <description>Twice daily doses of CHF6297 for 7 days</description>
    <arm_group_label>CHF6297 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 4)</intervention_name>
    <description>Twice daily doses of placebo matching CHF6297 for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Part 1, Part 2, Part 4 (Healthy subjects):

          -  Male subjects aged 18-55 years;

          -  Non smokers

          -  Lung function above 80% of predicted normal value

          -  Healthy subjects based on medical evaluation including medical history, physical
             examination, laboratory tests and cardiac testing

          -  ability to produce an adequate induced sputum sample (study part 4 only)

        Part 3 (COPD patients):

          -  Males and females aged 40-75 years

          -  Current or past smokers

          -  stable patients with a post-bronchodilator FEV1 between 40 and 80% of predicted normal
             value and FEV1/FVC ratio &lt;0.7

          -  Ability to produce a spontaneous and an adequate induced sputum sample

        Exclusion Criteria:

        Parts 1,2, 4 (Healthy subjects):

          -  Any clinically relevant abnormalities and/or uncontrolled diseases

          -  Abnormal laboratory values

          -  Recent respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results

          -  Positive cotinine, alcohol, drug of abuse tests

        Part 3 (COPD patients):

          -  Females of childbearing potential

          -  History of asthma

          -  Unstable concomitant diseases

          -  Abnormal relevant Holter ECG parameters

          -  Recent acute exacerbations of COPD or respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

